Mabwell (Shanghai) Bioscience Future Growth

Future criteria checks 2/6

Mabwell (Shanghai) Bioscience is forecast to grow earnings and revenue by 58.2% and 87.8% per annum respectively. EPS is expected to grow by 58.3% per annum. Return on equity is forecast to be -24.1% in 3 years.

Key information

58.2%

Earnings growth rate

58.3%

EPS growth rate

Biotechs earnings growth	43.1%
Revenue growth rate	87.8%
Future return on equity	-24.1%
Analyst coverage	Low
Last updated	13 Sep 2024

Recent future growth updates

Recent updates

Mabwell (Shanghai) Bioscience (SHSE:688062) Has Debt But No Earnings; Should You Worry?

Aug 19

Earnings and Revenue Growth Forecasts

SHSE:688062 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,779	-138	-29	43	5
12/31/2025	961	-609	-528	-374	5
12/31/2024	326	-903	-789	-966	5
9/30/2024	169	-1,074	-1,153	-888	N/A
6/30/2024	153	-1,085	-1,209	-923	N/A
3/31/2024	191	-1,018	-1,349	-961	N/A
12/31/2023	128	-1,053	-1,283	-783	N/A
9/30/2023	107	-936	-1,375	-774	N/A
6/30/2023	107	-945	-1,479	-777	N/A
3/31/2023	28	-976	-1,271	-611	N/A
12/31/2022	28	-955	-1,264	-719	N/A
9/30/2022	26	-947	-1,148	-657	N/A
6/30/2022	20	-853	-932	-550	N/A
3/31/2022	20	-833	-858	-578	N/A
12/31/2021	16	-770	-640	-422	N/A
9/30/2021	11	-699	-581	-392	N/A
12/31/2020	5	-643	-646	-515	N/A
12/31/2019	29	-928	-540	-354	N/A
12/31/2018	37	-225	-380	-156	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688062 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 688062 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 688062 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 688062's revenue (87.8% per year) is forecast to grow faster than the CN market (13.8% per year).

High Growth Revenue: 688062's revenue (87.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688062 is forecast to be unprofitable in 3 years.

Mabwell (Shanghai) Bioscience Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 8.5% to CN¥35.92

Recent updates

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA

New major risk - Share price stability

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer

Mabwell (Shanghai) Bioscience (SHSE:688062) Has Debt But No Earnings; Should You Worry?

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA

New minor risk - Share price stability

FDA Grants Orphan Drug Designation to 7MW3711

FDA Grants Fast Track Designation to Mabwell's 9MW2821 for the Treatment of Patients with Locally Advanced or Metastatic Nectin-4 Positive TNBC

Mabwell (Shanghai) Bioscience Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Mabwell Announces 9MW2821 Clinical Data

Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer

Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821

First quarter 2024 earnings released: CN¥0.51 loss per share (vs CN¥0.60 loss in 1Q 2023)

Price target increased by 8.5% to CN¥35.92

Full year 2023 earnings: EPS and revenues miss analyst expectations

Mabwell (Shanghai) Bioscience Co., Ltd., Annual General Meeting, Apr 29, 2024

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting

Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology

Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Fiscal Year 2023 Results on Apr 09, 2024

National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA

Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial

Insufficient new directors

New major risk - Financial position

Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs

Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor

New major risk - Financial position

Second quarter 2023 earnings released: CN¥0.43 loss per share (vs CN¥0.51 loss in 2Q 2022)

Mabwell (Shanghai) Bioscience Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Mabwell (Shanghai) Bioscience Co., Ltd. Announces the U.S. FDA approval of 9MW3811 for IND

Full year 2022 earnings released: CN¥2.44 loss per share (vs CN¥2.57 loss in FY 2021)

Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.67 loss per share (vs CN¥0.58 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.51 loss per share (vs CN¥0.58 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.55 loss per share (vs CN¥0.61 loss in 1Q 2021)

Full year 2021 earnings released: CN¥2.57 loss per share (vs CN¥2.26 loss in FY 2020)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies